StreetInsider.com News Articles

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

NEW YORK CITY, NY / ACCESS Newswire / July 25, 2026 / New to The Street, one of America's longest-running sponsored business television brands, today announced the broadcast of its latest episode, airing tonight at 6:30 PM ET on Bloomberg Television across the United States, with additional weekly distribution throughout Bloomberg's Latin America and MENA television networks.

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

Sat, 25 Jul 2026 13:10:00 -0400

The nationally televised program will feature in-depth executive interviews and company updates from:

RHINO Bitcoin (RHNO) RhinoBitcoin.com
Marina Decisions- Madhu Gulati with David Fagan co hosting
Medicus Pharma (MDCX)
Virtuix Holdings (VTIX)

Each segment is designed to provide investors with a

Form SCHEDULE 13G/A Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR

Thu, 23 Jul 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260723/26807262.html

Form SCHEDULE 13G/A Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR

Thu, 23 Jul 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260723/26807262.html

Lantern Pharma receives USPTO patent allowance for LP-184 biomarker

Thu, 23 Jul 2026 08:01:24 -0400

Lantern Pharma Inc. (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering biomarker-guided treatment with its drug candidate LP-184, also known as zirdafulven, in multiple solid tumor cancers.

The allowed claims, under U.S. Patent Application No. 17/230,821, cover methods of selecting and treating patients with ovarian, primary liver, kidney, or thyroid cancer using LP-184 based on elevated expression of three genes — PTGR1, PTPN14, and ASPH — identified in a patient tumor sample.

Kishor Bhatia, Ph.D., Chief Scientific Officer of Lantern Pharma, said in a statement: "PTGR1 is unique in that

Lantern Pharma receives USPTO patent allowance for LP-184 biomarker

Thu, 23 Jul 2026 08:01:24 -0400

Kishor Bhatia, Ph.D., Chief Scientific Officer of Lantern Pharma, said in a statement: "PTGR1 is unique in that

Lantern Pharma receives USPTO patent allowance for LP-184 biomarker

Thu, 23 Jul 2026 08:01:24 -0400

Kishor Bhatia, Ph.D., Chief Scientific Officer of Lantern Pharma, said in a statement: "PTGR1 is unique in that

Lantern Pharma receives USPTO patent allowance for LP-184 biomarker

Thu, 23 Jul 2026 08:01:24 -0400

Kishor Bhatia, Ph.D., Chief Scientific Officer of Lantern Pharma, said in a statement: "PTGR1 is unique in that

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thu, 23 Jul 2026 08:01:00 -0400

Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose
LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop